MapLight Therapeutics reported positive Phase 2 results for its schizophrenia medicine but the market response underscored how endpoint details can dominate clinical narratives. In a mid-stage study, MapLight said adults with sudden worsening of psychotic symptoms saw an average 4.5-point improvement on the primary schizophrenia symptom measure versus placebo with twice-daily dosing. However, MapLight’s once-daily regimen missed the primary endpoint, and the company said it is still analyzing whether a path forward exists for that dosing schedule. The company also pointed to more favorable results across secondary and exploratory outcomes, including a “robust signal” it says supports potential cognitive benefits. The readout matters for competitive positioning because Bristol Myers Squibb’s Cobenfy—also targeting muscarinic receptors—has already gained FDA approval and posted large improvements across pivotal PANSS studies. Cross-trial comparisons remain uncertain, but the timing of MapLight’s data sets up a direct investor question on differentiation. MapLight’s near-term strategy is likely to hinge on which dosing schedule is pursued, and whether cognitive or other secondary outcomes can be translated into additional trials that strengthen the case against existing approved therapies.